Introduction
============

Allogenic blood transfusion (ABT) is frequently required in patients undergoing cardiac surgery because of hemodilution and perioperative bleeding \[[@b1-kjtcv-52-385]\]. ABT during the perioperative period can cause adverse events such as infectious diseases, lung injury, and immune rejection \[[@b2-kjtcv-52-385],[@b3-kjtcv-52-385]\]. In addition, several reports have found postoperative ABT to be associated with an increased risk of early and late morbidity or mortality \[[@b4-kjtcv-52-385]\]. Over the past few decades, various efforts have been made to reduce the frequency of ABT to improve outcomes and reduce ABT-related complications \[[@b1-kjtcv-52-385]\].

Recent studies have shown that ABT during cardiac surgery can be reduced through various blood conservation strategies, such as intraoperative autologous blood donation, retrograde autologous priming (RAP), using shorter circuits, and postoperative hemofiltration \[[@b5-kjtcv-52-385]--[@b9-kjtcv-52-385]\]. Additionally, preoperative autologous blood donation (PABD) has been proposed as a blood conservation method \[[@b10-kjtcv-52-385]\].

The use of PABD markedly increased from the 1980s to the early 1990s. PABD is known to have several advantages. A meta-analysis of multiple studies demonstrated that PABD reduced postoperative ABT \[[@b11-kjtcv-52-385]\]. This effect can reduce transfusion-transmitted viral or infectious diseases and can avoid immune-mediated complications by reducing the use of allogenic blood or blood components. PABD also increases erythropoietin secretion and promotes blood production by removing a considerable amount of blood from the patient \[[@b12-kjtcv-52-385]\].

Recently, however, there has been controversy regarding the effort-effectiveness of PABD. The safety of ABT has been ensured compared to the past, and the frequency of cardiac surgery-related blood transfusion has been reduced through advances in technologies and surgical strategies \[[@b13-kjtcv-52-385],[@b14-kjtcv-52-385]\]. The effect of PABD in this recent strict setting for blood conservation and minimally invasive cardiac surgery (MICS) has not yet been well established. Therefore, we conducted this study to evaluate the effects of additional PABD in the recent rigorous blood conservation setting during MICS in terms of clinical outcomes and the frequency of ABT.

Methods
=======

1) Patients
-----------

Our study included 325 patients who underwent MICS performed by a single surgeon from January 2015 to July 2017. Given that we introduced the PABD program in January 2016, patients who underwent the procedure in 2015 were included as controls (the non-PABD group), and those who underwent the procedure in 2016 comprised the cohort group (the PABD group) ([Fig. 1](#f1-kjtcv-52-385){ref-type="fig"}).

Patients with preoperative hemoglobin (Hb) levels \>11 g/dL were included in this study. We excluded patients with severe aortic stenosis, coronary artery disease, old age (\>70 years), low body weight (\<50 kg in men, \<45 kg in women), infective endocarditis, and sternotomy. Urgent and emergent operations were also excluded. The exclusion criteria for blood donation were in accordance with the World Health Organization blood donation guideline \[[@b15-kjtcv-52-385]\]. Ultimately, this study enrolled 69 patients in the PABD group and 44 in the non-PABD group.

Data from the PABD group were collected prospectively after obtaining Pusan National University Yangsan Hospital Institutional Review Board approval (IRB approval no., L-2017405) and patients' informed consent. We compared the prospective PABD group to the non-PABD group reviewed retrospectively.

2) Preoperative autologous blood donation
-----------------------------------------

After the choice was made at the outpatient clinic for the patients to undergo surgery, patients who were able to donate blood were referred to the Department of Laboratory Medicine for preoperative blood donation. No patients withdrew from blood donation for surgery. PABD was performed 2--3 weeks prior to surgery. Male and female patients donated 400 mL and 320 mL of blood, respectively. Each blood bag contained 100 mL of blood preservation fluid and was used to store 400--500 mL of whole blood. The blood bags were stored at 0°C--4°C in a blood bank. After blood donation, patients were infused with 500 mL of normal saline and instructed to take 256 mg of ferric sulfate per day. Blood donation was stopped immediately in the event of any side effects, such as dizziness or syncope. One patient showed dizziness during PABD; however, the symptom improved after saline infusion. No other patients complained of any other symptoms. Only 1 pack of blood was donated at a time, and the number of blood donations was determined according to the period before surgery. All blood donations were completed at least 1 week before surgery.

3) Transfusion strategy
-----------------------

The trigger for intraoperative transfusion was an Hb level \<6 g/dL or hematocrit (HCT) \<18%. The trigger for postoperative packed red blood cell (PRBC) transfusion was an Hb level \<7 g/dL, HCT \<21%, or evidence of persistent bleeding (\>200 mL/hr for at least 3 hours). The trigger for platelet transfusion was a platelet count ≤70,000/μL. The same transfusion guidelines were applied to both groups \[[@b15-kjtcv-52-385]\]. In the PABD group, the stored autologous blood was used first when blood transfusion was needed. After transfusion of the stored autologous blood, allogenic blood was transfused according to the abovementioned criteria. All stored blood obtained by PABD was used during the perioperative period, and no blood was wasted.

4) Blood conservation strategy during minimally invasive cardiac surgery
------------------------------------------------------------------------

In addition to PABD, various strict strategies for blood conservation were implemented to reduce the need for ABT during and after MICS. The cardiopulmonary circuit was made as short as possible to reduce the priming volume, and a cell saver was used routinely in all MICS procedures. We tried to perform RAP (n=35, 31%) in as many patients as possible, and post-cardiopulmonary bypass ultra-hemofiltration was performed in all patients. Drugs for hemostasis, such as tranexamic acid and amino-methyl-benzoic acid, were routinely used postoperatively.

5) Clinical follow-up and definition
------------------------------------

Arterial blood gas testing every 2 to 4 hours and 2 complete blood count tests (CBCs) were used to monitor Hb within 24 hours after surgery. If there was no bleeding tendency, Hb levels were confirmed by a routine CBC once every 2 days. An additional CBC was performed 1 week after discharge at the outpatient clinic.

Early mortality was defined as death within 30 days after surgery. Low cardiac output syndrome was defined as the administration of a combination of dopamine and dobutamine of 20 μg/kg/min or more, or a combination of norepinephrine and epinephrine at 0.2 μg/kg/min or more for hemodynamic stability. Any one of the following circumstances was considered a pulmonary complication: prolonged ventilation support (\>24 hours), clinically confirmed pneumonia, or re-intubation. The following criteria were used to define renal failure: new-onset dialysis, a 3-fold increase in the serum creatinine level, anuria for 12 hours after surgery, or a urine output \<0.3 mL/kg/hr for 24 hours.

6) Statistical methods
----------------------

The data were analyzed using IBM SPSS Software for Windows ver. 22.1 (IBM Corp., Armonk, NY, USA) and presented as means, numbers, or ratios as appropriate. The Pearson chi-square test was used for descriptive univariate statistics, whereas the t-test was used for normally distributed data. The Mann-Whitney U-test was used for group comparisons of continuous non-Gaussian distributed variables. Two-tailed p-values were derived from the calculated test statistics, and p-values \<0.05 was considered to indicate statistical significance.

Results
=======

1) Baseline characteristics and surgical profiles
-------------------------------------------------

There were no significant differences in the baseline characteristics between groups, except for the preoperative Hb levels. Hb levels were significantly higher in the non-PABD group on the day before surgery ([Table 1](#t1-kjtcv-52-385){ref-type="table"}). The average EuroSCORE II (European System for Cardiac Operative Risk Evaluation II) of all patients was 1.46, demonstrating that relatively low-risk patients were included in the study.

All patients in both groups underwent a right mini-thoracotomy with peripheral cannulation. There were no significant differences in the type of surgery performed between the 2 groups, and the car diopulmonary bypass and aortic cross-clamp times were similar ([Table 2](#t2-kjtcv-52-385){ref-type="table"}).

2) Clinical outcomes
--------------------

There were no cases of early mortality in either group, and the incidence of major complications, such as acute renal failure, low cardiac output syndrome, and pulmonary complications, was not significantly different between the PABD and the non-PABD groups. In total, 100 patients (88%) underwent immediate extubation in the operating room after surgery. Trend of hemoglobin changes during the perioperative period ([Fig. 2](#f2-kjtcv-52-385){ref-type="fig"}). The amount of chest tube drainage and the incidence of ABT tended to be higher in the PABD group, although these differences were not statistically significant ([Table 3](#t3-kjtcv-52-385){ref-type="table"}). The duration of the intensive care unit (ICU) stay was within 24 hours, and all patients were discharged within 1 week. During a mean follow-up of 33.8±8.6 months, there were 2 late deaths. The causes of death were a traffic accident and trauma, not medical problems.

3) Allogenic blood transfusion
------------------------------

ABT was performed in 10 patients (8.8%) during the study period. Eight patients were in the PABD group and 2 in the non-PABD group, respectively. All 10 patients who underwent transfusion received fresh frozen plasma, whereas 9 patients received PRBC and 5 patients received platelets. Seven patients underwent transfusion in the operating room and ICU, and 5 patients underwent transfusion in the ICU owing to an increased chest tube drainage volume and a decreased Hb level. Two patients, both in the PABD group, underwent exploration for bleeding control. There was no additional ABT after discharge at the outpatient clinic.

Discussion
==========

Through the evaluation of 113 relatively low-risk patients without preoperative anemia, the present study showed that the overall clinical outcomes were good, with no early mortality and a low incidence of major complications in both the PABD and non-PABD groups. Although the PABD group showed higher Hb levels than the non-PABD group during the early postoperative period, there were no significant differences in the clinical outcomes between both groups. Although there were no statistically significant differences, the incidence of ABT was higher in the PABD group (2.3% versus 11.6%), contrary to our expectations. In strict blood conservation settings where MICS is the mainstay, the PABD strategy was safe and feasible, however its effort-effectiveness was less clinically meaningful in the present study.

In the 1980s and early 1990s, the use of PABD markedly increased to avoid ABT-related complications, such as transmission of the hepatitis B, C, and human immunodeficiency viruses \[[@b16-kjtcv-52-385]\]. Over the past 20 years, the safety of allogenic transfusions has been established, the risk of ABT-related infections has significantly reduced, and the use of PABD has also decreased \[[@b12-kjtcv-52-385]\]. There are some potential issues of concern regarding PABD, such as sudden symptom deterioration, an increased infection rate, and cumbersomeness for the patient. Despite this trend, some clinicians still use PABD as a blood conservation strategy. A meta-analysis of multiple surgical procedures revealed that the PABD group was less likely to require allogenic transfusion than the non-PABD group (odds ratio \[OR\], 0.17; 95% confidence interval \[CI\], 0.08--0.32). However, overall transfusion (autologous+ allogenic) was more frequent in the PABD group (OR, 3.03; 95% CI, 1.7--5.4) \[[@b11-kjtcv-52-385]\]. In the present study, all blood stored through PABD was transfused to each patient. The frequency of ABT---excluding autologous transfusion---did not show a statistically significant difference; however, numerically, ABT was 5 times as frequent in the PABD group (2.3% versus 11.6%, p=0.15). Our results showed that PABD was ineffective in reducing the rate of ABT.

The reported frequency of perioperative ABT in cardiac surgery ranged from 40% to 90% in various studies \[[@b1-kjtcv-52-385]\]. However, ABT related to cardiac surgery is gradually becoming less common due to advances in surgical strategies and technologies \[[@b14-kjtcv-52-385]\]. In this cohort, only 8.0% of patients received ABT during the perioperative period. These results may be due to the fact that these patients underwent MICS, received strict transfusion interventions, and were relatively low-surgical-risk patients.

Nevertheless, this study may have some clinical implications. Gradually, MICS is expanding in cardiac surgery, and the present paper is the first report of the effects of PABD in patients undergoing MICS. Additionally, this study sought to determine the effects of PABD in recent MICS procedures with improved blood transfusion rates and a strict blood conservation strategy.

In contrast to our expectations, ABT was more common in the PABD group, and a larger amount of fluid was drained via chest tubes within 12 hours in the PABD group. The specific causes of these results are unclear; however, there are some possible explanations. First, it is assumed that surgery was performed before Hb levels completely recovered after the blood donation. Second, the autologous blood was stored as whole blood without separation of blood components, which likely resulted in lost functionality of platelets and clotting factors. Third, additional PABD may have less clinical impact in situations where strict blood conservation strategies are already in place.

The effort-effectiveness of PABD has been a topic of debate. Recently, the safety and availability of allogenic blood components have been ensured, raising more controversies about the effort-effectiveness of PABD, which requires additional efforts to be made by several medical team members and use of resources. PABD also imposes additional costs and hospital visits on patients, and sometimes these procedures cause discomfort to the patients. In addition, the effort-effectiveness of PABD becomes even more unfavorable if its clinical effectiveness cannot be guaranteed, as in the present study.

This study has several limitations. First, the sample size and the number of ABT events were insufficient to yield statistically significant results. Second, it is unreasonable to apply these results to the general population, because of the exclusion of high-risk patients after the selection of patients suitable for blood donation. Patients undergoing certain commonly performed procedures, such as coronary artery bypass grafting or aortic valve replacement due to aortic stenosis, were excluded from this study because they were vulnerable to ischemia; thus, PABD was not possible. Since these patients were excluded from this study, it is difficult to apply our results to these patients. Third, a historical control group was compared with a prospective cohort group to increase the number of patients included in this study. Therefore, the patients in each group did not undergo surgery during the same period; thus, there may have been differences that we could not identify. However, the baseline characteristics of the 2 groups were similar without adjusting the data, all procedures were performed by a single surgeon, and the prospectively collected data boosted the reliability of the study. In addition, the operative date of the cohort and control groups did not differ by more than 2 years.

In conclusion, the present study found that additional PABD in the setting of strict policies for blood conservation was ineffective in reducing ABT during MICS, especially in relatively young and healthy patients with low surgical risk. Despite a great deal of effort and additional cost, this method did not have clinical benefits in the early postoperative period.
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###### 

Preoperative baseline characteristics (N=113)

  Characteristic                                              Non-PABD group (n=44)   PABD group (n=69)   p-value
  ----------------------------------------------------------- ----------------------- ------------------- ---------
  Age (yr)                                                    48.4±11.5               47.4±14.1           0.69
  Female                                                      28 (63.6)               35 (50.7)           0.25
  Body weight (kg)                                            63.1±11.4               65.3±12.6           0.35
  Hypertension                                                17 (38.6)               24 (34.8)           0.83
  Diabetes mellitus                                           4 (9.1)                 5 (7.2)             0.45
  Prior cardiac surgery                                       1 (2.3)                 2 (2.9)             \>0.99
  New York Heart Association functional class III or IV       12 (27.3)               17 (24.6)           \>0.99
  Left ventricular ejection fraction                          62.0±9.0                60.4±8.5            0.37
  EuroSCORE II[a)](#tfn3-kjtcv-52-385){ref-type="table-fn"}   1.0 (0.8--1.7)          0.9 (0.7--1.5)      0.95
  Preoperative hemoglobin (g/dL)                              13.4±2.0                12.5±1.6            0.012

Values are presented as mean±standard deviation, number (%), or median (range).

PABD, preoperative autologous blood donation.

European System for Cardiac Operative Risk Evaluation II.

###### 

Patients' surgical profiles (N=113)

  Variable                            Non-PABD group (n=44)   PABD group (n=69)   p-value
  ----------------------------------- ----------------------- ------------------- ---------
  Main procedure                                                                  
   Atrial septal defect repair        15 (34.1)               25 (36.2)           0.98
   Ventricular septal defect repair   2 (4.5)                 9 (13.0)            0.25
   Aortic valve surgery               3 (6.8)                 11 (15.9)           0.25
   Mitral valve surgery               22 (50.0)               25 (36.2)           0.21
   Aortic+mitral valve surgery        1 (2.3)                 0                   0.20
   Others                             3 (6.8)                 2 (2.9)             0.60
  Concomitant procedure                                                           
   Tricuspid repair                   5 (11.4)                7 (10.1)            \>0.99
   Ablation of atrial fibrillation    12 (27.3)               16 (23.2)           \>0.99
  Cardiopulmonary bypass time (min)   84.9±39.4               85.4±38.9           0.94
  Aortic cross-clamp time (min)       65.6±28.7               59.7±30.4           0.36

Values are presented as number (%) or mean±standard deviation.

PABD, preoperative autologous blood donation.

###### 

Clinical outcomes during hospitalization after surgery

  Variable                                          Non-PABD group (n=44)   PABD group (n=69)   p-value
  ------------------------------------------------- ----------------------- ------------------- ---------
  Early mortality                                   0                       0                   
  Intensive care unit stay (day)                    1.2±1.4                 1.2±0.5             0.85
  Hospital stay (day)                               4.0 (3--5)              4.0 (3--5)          0.91
  Major complications                                                                           
   Acute renal failure                              0                       0                   
   Pulmonary complication                           3 (6.8)                 2 (2.9)             0.60
   Low cardiac output syndrome                      3 (6.8)                 6 (8.7)             \>0.99
   Reoperation for bleeding control                 0                       2 (2.6)             0.68
  Chest tube drainage volume within 12 hours (mL)   205 (150--372)          234 (173--346)      0.17
  Allogenic red blood cell transfusion              1 (2.3)                 8 (11.6)            0.15

Values are presented as number (%), mean±standard deviation, or median (range).

PABD, preoperative autologous blood donation.
